secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001493152-26-006473
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IMDX raises $26M in registered direct offering; funds heart transplant rejection test development
--------------------------------------------------------------------------------

- Gross proceeds ~$26M from 4,525,976 shares/pre-funded warrants at $5.75/unit; net proceeds ~$24.5M.
- Proceeds to expand GraftAssure product line into heart transplant rejection testing, beyond current kidney focus.
- Bio-Rad Laboratories, significant shareholder, participated on same terms as other institutional investors.
- Offering closed Feb 12, 2026; Lake Street Capital Markets acted as sole placement agent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315226006473/0001493152-26-006473-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315226006473/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-006473

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer